Vertex Reports Second-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- S&P 500 and Nasdaq slip as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
Vertex Pharma (VRTX) Tops Q2 EPS by 19c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus
July 31, 2019 4:04 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $1.26, $0.19 better than the analyst estimate of $1.07. Revenue for the quarter came in at $941.29 million versus the consensus estimate of $885.58 million.
"We have made tremendous progress across our business in 2019 thus far. In... More
